Cargando…
Blocking the CGRP Receptor: Differences across Human Vascular Beds
Multiple drugs targeting the calcitonin gene-related peptide (CGRP) receptor have been developed for the treatment of migraine. Here, the effect of the small-molecule CGRP receptor antagonist zavegepant (0.1 nM–1 µM) on CGRP-induced relaxation in isolated human coronary arteries (HCAs) was investiga...
Autores principales: | de Vries, Tessa, Boucherie, Deirdre M., van den Bogaerdt, Antoon, Danser, A. H. Jan, MaassenVanDenBrink, Antoinette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459004/ https://www.ncbi.nlm.nih.gov/pubmed/37630989 http://dx.doi.org/10.3390/ph16081075 |
Ejemplares similares
-
The potential danger of blocking CGRP for treating migraine in CADASIL
patients
por: de Boer, Irene, et al.
Publicado: (2020) -
Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022) -
Endothelin-converting-enzyme 1 inhibition and CGRP receptor recycling in human coronary and middle meningeal arteries
por: Labruijere, S, et al.
Publicado: (2013) -
Could erectile dysfunction be a side effect of CGRP inhibition? A case report
por: Al-Hassany, Linda, et al.
Publicado: (2021) -
Influence of varying estrogen levels on trigeminal CGRP release in healthy women
por: Ibrahimi, K, et al.
Publicado: (2013)